Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
Standard
Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. / Vincenti, F; Nashan, Björn; Light, S.
In: TRANSPL P, Vol. 30, No. 5, 5, 1998, p. 2155-2158.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
Vincenti, F, Nashan, B & Light, S 1998, 'Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.', TRANSPL P, vol. 30, no. 5, 5, pp. 2155-2158. <http://www.ncbi.nlm.nih.gov/pubmed/9723424?dopt=Citation>
APA
Vincenti, F., Nashan, B., & Light, S. (1998). Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. TRANSPL P, 30(5), 2155-2158. [5]. http://www.ncbi.nlm.nih.gov/pubmed/9723424?dopt=Citation
Vancouver
Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. TRANSPL P. 1998;30(5):2155-2158. 5.
Bibtex
@article{1d251eb43c19495abcdf2c440b64e18c,
title = "Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.",
author = "F Vincenti and Bj{\"o}rn Nashan and S Light",
year = "1998",
language = "Deutsch",
volume = "30",
pages = "2155--2158",
journal = "TRANSPL P",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",
}
RIS
TY - JOUR
T1 - Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
AU - Vincenti, F
AU - Nashan, Björn
AU - Light, S
PY - 1998
Y1 - 1998
M3 - SCORING: Zeitschriftenaufsatz
VL - 30
SP - 2155
EP - 2158
JO - TRANSPL P
JF - TRANSPL P
SN - 0041-1345
IS - 5
M1 - 5
ER -
